Statens Serum Institut
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1902-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.ssi.dk/
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: H107e/CAF®10b - full adjuvant doseBiological: H107eBiological: CAF®10bBiological: H107e/CAF®10bBiological: H107e/CAF®10b - low adjuvant doseBiological: i.m. placeboBiological: Full dose intranasal H107eBiological: Low dose intranasal H107eBiological: i.d. placeboBiological: Intranasal H107e
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 140
- Registration Number
- NCT06050356
- Locations
- 🇿🇦
Aurum Institute, Pretoria, Gauteng, South Africa
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
Phase 1
Completed
- Conditions
- Trachoma
- Interventions
- Biological: CTH522-CAF01 IMBiological: CTH522-CAF09b IMBiological: CTH522 TOBiological: CTH522 IDBiological: Placebo (Saline)
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 65
- Registration Number
- NCT03926728
- Locations
- 🇬🇧
NIHR Imperial Center for Translational and Experimental Medicine, London, United Kingdom
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: IPV-Al SSI
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 666
- Registration Number
- NCT03671616
- Locations
- 🇵🇦
Cevaxin, Panama City, Panama
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: IPV SSIBiological: IPV-Al SSI
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 1002
- Registration Number
- NCT03032419
- Locations
- 🇵ðŸ‡
5 sites in Philippines, Manila, Philippines
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: IPV SSIBiological: IPV-Al SSI
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 800
- Registration Number
- NCT03025750
- Locations
- 🇵🇦
Cevaxin, Panama City, Panama
Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years
Phase 1
Completed
- Conditions
- Chlamydia Trachomatis
- Interventions
- Biological: CTH522-CAF01Biological: CTH522-Al(OH)3Biological: Placebo
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 35
- Registration Number
- NCT02787109
- Locations
- 🇬🇧
NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital, London, United Kingdom
Infection and Adverse Pregnancy Outcome
- Conditions
- Preterm Birth
- Interventions
- Other: No intervention
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 2200
- Registration Number
- NCT02673216
- Locations
- 🇩🇰
Skejby University Hospital, Aarhus, Denmark
3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants
Phase 2
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: IPV Vaccine SSIBiological: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 824
- Registration Number
- NCT02347423
- Locations
- 🇩🇴
Hospital Maternidad Nuestra de la Altagracia, Santo Domingo, Dominican Republic
3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents
Phase 1
Completed
- Conditions
- Immunization, Booster
- Interventions
- Biological: 1/3 IPV-Al SSI, manufactured by SSI, DenmarkBiological: IPV SSI, manufactured by SSI, DenmarkBiological: 1/5 IPV-Al SSI, manufactured by SSI, DenmarkBiological: 1/10 IPV-Al SSI, manufactured by SSI, Denmark
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 240
- Registration Number
- NCT02280447
- Locations
- 🇩🇰
CCBR, Vejle, Denmark
Pneumococcal Vaccination of Crohn Patients
Phase 4
Completed
- Conditions
- Crohns Disease
- Interventions
- Biological: Prevenar 13Biological: Pneumovax
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 151
- Registration Number
- NCT01947010
- Locations
- 🇩🇰
Statens Serum Institut, Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath